Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country

Autor: Jajac-Bručić, Lana, Grubišić-Čabo, Filip, Jović- Zlatović, Josipa, Krečak, Ivan
Rok vydání: 2021
Předmět:
Zdroj: Libri Oncologici : Croatian Journal of Oncology
Volume 49
Issue 2-3
Libri Oncologici, Vol 49, Iss 2-3, Pp 76-79 (2021)
ISSN: 2584-3826
0300-8142
Popis: In randomized clinical trials, trifluridine / tipiracil (TT) demonstrated beneficial effects on progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). The aim of this unicentric study was to evaluate the efficacy and safety of TT in patients with refractory mCRC in everyday clinical practice. Treatment outcomes of 20 patients were retrospectively analyzed. The median OS was 6.25 months (range 1-18) and the median PFS was 3 months (range 2–13). The most common (80%) side effect of TT was neutropenia and 35% of patients had neutropeniagrades 3 of 4; however, only two patients (10%) had neutropenic fever and no deaths wereattributable to neutropenia. In conclusion, treatment outcomes in this real-life study seem comparable to those from randomized clinical trials.
U randomiziranim kliničkim studijama trifluridin/tipiracil (TT) je pokazao povoljan učinak na preživljenje bez progresije bolesti (PFS) i na ukupno preživljenje (OS) u bolesnika s refraktornim metastatskim kolorektalnim karcinomom (mKRK). Cilj ovog unicentričnog istraživanja bio je procijeniti učinkovitost i sigurnost primjene TT kod bolesnika s refraktornim mKRK u svakodnevnoj kliničkoj praksi. Retrospektivno su analizirani ishodi liječenja 20 bolesnika. Medijan OS bio je 6.25 mjeseci (raspon 1-18) a medijan PFS 3 mjeseca (raspon 2-13). Najčešća (80%) nuspojava TT bila je neutropenija, u 35% bolesnika gradusa 3 i 4. Ipak, u samo dva bolesnika (10%) zabilježena je neutropenična vrućica, a nijedan bolesnik nije preminuo zbog neutropenije. Zaključno, ishodi liječenja bolesnika s mKRK s TT u svakodnevnom kliničkom radu usporedivi su s onima iz randomiziranih kliničkih studija.
Databáze: OpenAIRE
Externí odkaz: